Leonard G. Gomella, MD
Insights about PSA screening, genomics, and what’s new in the areas of imaging, antiandrogen therapy, radiation therapy, immunotherapy, and radiopharmaceuticals will be offered during the 7th Annual Interdisciplinary Prostate Cancer Congress (IPCC) at Manhattan’s Crowne Plaza Times Square.
Rounding out the one-day conference will be two moderated case-based discussions structured to resemble multidisciplinary tumor boards.
The aim of the annual conference is to provide concise updates on best practices, investigational strategies, trends, and emerging data relevant to community urologists and medical, surgical, and radiation oncologists—helping to inform and sustain well-rounded teams in the treatment of the disease. This year’s conference will include discussions of state-of-the-art treatments, guidelines, controversies, and clinical challenges, as well as question-and-answer sessions.
The educational activity is open not only to physicians who treat prostate cancer, but also to fellows, nurse practitioners, nurses, physician assistants, pharmacists, and other healthcare professionals interested in the disease.
One of the conference’s three co-chairs, Leonard G. Gomella, MD, FACS, said that the value of the event is its focus on practical applications of recent developments in the field.
“The focus of the meeting is not theoretical,” he said. “It’s a practical understanding of all the changes going on now in the field of prostate cancer. There are changes occurring at all levels, from initial diagnosis to treatment of advanced disease, and a conference like this allows direct interaction with thought leaders who not only write and do research, but are providers who work every day in the area. It’s an opportunity for participants to ask questions and understand how much we know and don’t know. When they go back to the patient setting, they can actually use [this information] in their daily patient care.”
Gomella is the Bernard W. Godwin professor of Prostate Cancer at Jefferson Medical College, and is associate director and chairman of the Department of Urology at the Kimmel Cancer Center in Philadelphia, Pennsylvania.
The conference will have two additional co-chairs:
Daniel P. Petrylak, MD, professor of Medicine, Medical Oncology director, and Prostate and GU Medical Oncology director of the Prostate Cancer Translational Research Program at the Yale Cancer Center in New Haven, Connecticut; and
A. Oliver Sartor, MD, Laborde Professor of Cancer Research in the Medicine and Urology Departments at the Tulane University School of Medicine in New Orleans, Louisiana.
In addition, three faculty members will be part of the event:
E. David Crawford, MD, professor of Urologic and Radiation Oncology and head of the Section of Urologic Oncology at the University of Colorado at Denver and its hospital. He is also chairman and founder of the Prostate Conditions Education Council in Denver;
Robert Dreicer, MD, MS, FACP, FASCO, professor of Medicine at the Cleveland Clinic Lerner College of Medicine and chairman of the Department of Solid Tumor Oncology at the Cleveland Clinuic’s Taussig Cancer Institute; and
Peter B. Schiff, MD, PhD, FASTRO, professor and vice chairman of the Department of Radiation Oncology at the NYU School of Medicine in New York City.
In addition to moderating part of the day, Gomella will address practical considerations in prostate cancer care during the meeting, focusing on androgen deprivation therapy and management of the side effects that can come with keeping testosterone levels low for long periods of time.
Petrylak, meanwhile, will review the year’s developments and trends in prostate cancer; give a therapeutic overview of castration-resistant prostate cancer (CPRC); speak about novel imaging modalities; and take part in the two debates on challenging cases with the other co-chairs and faculty—one in the active surveillance setting and the other focused on best practices for advanced disease.
Petrylak will suggest that “we need to be rethinking how and when we image patients with advanced prostate cancer, since early recognition of metastatic prostate cancer is important and may lead to improved survival,” Gomella said.